Earnings
Home›Earnings›Results›BWX Technologies to sell medical isotopes unit to Nord…
BWX Technologies to sell medical isotopes unit to Nordic Capital
The deal is valued at up to $800 million, and BWX said commercial operations revenue rose 72% year over year to $302.5 million in its August 2026 second-quarter earnings update.
BWX Technologies agreed to sell its medical isotopes business to Nordic Capital for up to $800 million, shifting the company’s focus toward nuclear energy and defense, according to MarketBeat Ratings.
The company said the sale is intended to provide immediate liquidity and funding for scaling small modular reactor production and expanding naval propulsion output, while also reducing exposure to a unit it described as tangential to its core nuclear capabilities.
MarketBeat Ratings also noted that BWX retained a minority ownership stake in the divested medical entity, which the outlet said is designed to give shareholders some upside tied to the radiopharmaceutical market.
In the company’s August 2026 second-quarter earnings update, BWX Technologies reported that commercial operations revenue climbed 72% year over year to $302.5 million, framing the pivot toward commercial nuclear applications as already gaining traction.